Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

This study is testing an artificial liver support system (ALSS) — a machine that temporarily helps a damaged liver filter waste from the blood — for people with liver cancer (HCC) who develop serious liver damage as a side effect of immunotherapy (checkpoint inhibitor drugs). This complication is called immune checkpoint inhibitor-induced liver failure. **You may be eligible if...** - You are between 18 and 65 years old - You have liver cancer (HCC) and also have chronic hepatitis B infection - You have received immunotherapy (checkpoint inhibitor drugs) within the past 3 months - You have developed severe liver damage as a result (very high liver enzymes and bilirubin levels) - Your platelet count and other key labs meet the required thresholds **You may NOT be eligible if...** - You have another active liver disease or another type of cancer - You are pregnant or breastfeeding - You have HIV or severe autoimmune disease - You have active uncontrolled bleeding or blood clotting problems - You received artificial liver support within the past week Talk to your doctor to see if this trial is right for you.